ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021
Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Lactoferrin Levels in Cerebrospinal Fluid Exhibit Differential Associations with Alzheimer's Disease.Research square · 2026Article
- Nano-based spectroscopic approaches for early diagnosis of Alzheimer's disease: critical insights into amyloid-β and tau biomarker biology and detection tools.Biophysical reviews · 2026Review
- The role of salivary lactoferrin as a potential biomarker for periodontal disease: a systematic review and meta-analysis.Frontiers in oral health · 2026Review
- Salivary lactoferrin levels in Down Syndrome: a case-control study.Brain, behavior, & immunity - health · 2025Article
- Reduced Salivary Lactoferrin Levels in Early-Onset Alzheimer's Disease.Aging and disease · 2024Article
- Obtaining a Reliable Diagnostic Biomarker for Diabetes Mellitus by Standardizing Salivary Glucose Measurements.Biomolecules · 2022Article
- Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients.Frontiers in immunology · 2022Review
- Salivary Lactoferrin Expression in a Mouse Model of Alzheimer's Disease.Frontiers in immunology · 2021Article
- Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for new, robust, and reproducible biomarkers for Alzheimer's disease (AD) diagnosis is a challenge. We recently reported that salivary lactoferrin (Lf) could be presented as new biomarker candidate for AD, being both non-invasive and cost-effective, as well as having appropriate diagnostic performance for the clinical detection of AD subjects. Saliva is an attractive sample type for biomarker-based testing approaches for several other diseases; however, its composition may change under certain circumstances. It is therefore critical to maintain a consistent salivary handling protocol, considering possible extrinsic factors that may influence salivary Lf concentration. In this work, we analyzed salivary Lf concentration under different handling conditions and donor-dependent factors including age, inter-diurnal variations, physical activity, and pharmacological treatments. Our aim was to evaluate the influence of such conditions on salivary Lf concentration. In conclusion, we found that most of these extrinsic factors should be considered in the future when using Lf as a predictive biomarker for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.